Clinical TrialAug 6, 2026, 04:13 PM
Psyence BioMed Doses Patients in Phase IIb Trial for NPX-5
AI Summary
PSYENCE BIOMEDICAL LTD. announced that patients have been dosed in its Phase IIb clinical trial for NPX-5, targeting Adjustment Disorder in cancer patients within palliative care. The company projects top-line results for this trial in the first half of 2027. PBM also highlighted its strategic equity stake in PsyLabs, which provides GMP-compliant manufacturing of natural psychedelics and an ethically sourced supply of iboga bark, supporting a vertically integrated biopharmaceutical platform. The company maintains a strong cash position with no debt.
Key Highlights
- Patients dosed in Phase IIb clinical trial for NPX-5.
- Phase IIb trial targets Adjustment Disorder in cancer patients.
- Top-line results for Phase IIb trial projected for H1 2027.
- Psyence BioMed holds strategic equity in PsyLabs for manufacturing.
- PsyLabs provides GMP-compliant natural psychedelics and iboga supply.
- Company has no debt and a strong cash position.
- FDA Pre-IND feedback received for NPX-5 development.
- Phase IIb trial involves 87 patients across three dosage arms.
Price Impact
More from PBM